Lorlatinib monotherapy (ALK+ NSCLC, 1L OR post-2G TKI)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-LORLATINIB`

ID	`REG-LORLATINIB-NSCLC`
Type	Regimen
Status	pending_clinical_signoff
Diseases	None declared
Sources	`SRC-ESMO-NSCLC-METASTATIC-2024` `SRC-NCCN-NSCLC-2025`

Notes

CROWN: 3-year PFS 64% (lorlatinib) vs 19% (crizotinib) — most active ALK 1L. Cognitive AE management requires careful patient selection.

Used By

Indication

IND-NSCLC-ALK-2L-LORLATINIB - IND-NSCLC-ALK-2L-LORLATINIB